Vinati Organics delivered strong quarterly results with Q2FY26 PAT increasing 20.3% year-on-year to ₹127.6 crore, as reported by Prabhudas Lilladher. This performance demonstrates the company's ability to navigate input cost pressures and maintain profitability. The sequential growth reflects effective cost management and pricing strategies implemented by the management team. The company's ability to deliver consistent quarterly growth despite challenging market conditions positions it well for future expansion plans.
Prabhudas Lilladher has issued an 'Accumulate' rating on Vinati Organics with a target price of ₹1,475 in its research report dated May 14, 2026. According to the report, the brokerage values the company at 30x FY28E EPS, while the stock is currently trading at 26x FY28E EPS. The recommendation reflects confidence in the company's growth prospects despite recent quarterly challenges and margin pressures from higher raw material costs. The strong Q2FY26 PAT performance of 20.3% year-on-year growth further validates this positive outlook.
The antioxidants segment demonstrated strong performance with 25% volume growth and contributed 12%-14% to overall revenue. According to Prabhudas Lilladher, this segment has a peak revenue potential of ₹7 billion. The company has guided for sustainable EBITDA margin of 26%-27% going forward. Revenue contribution from new products including MEHQ and guaiacol is experiencing delays in plant stabilization, pushing their anticipated substantial contribution to H2FY27 rather than the original timeline. This delay places a greater near-term emphasis on the performance of established product lines and the company's ability to execute its pricing strategy effectively.
Additional plants for upcoming products such as 4MAP, TAA, and PTAP are expected to be operationalized in FY27, providing further medium-term growth visibility. As reported by Prabhudas Lilladher, these developments are expected to contribute to the company's expansion strategy and long-term revenue growth prospects. The company faces persistent risks including potential for losing price-sensitive customers if competitors absorb temporary cost increases, with the staggered launch of new products meaning near-term growth heavily depends on sustained performance of current antioxidant offerings and successful ramp-up of planned expansions without further setbacks.
